Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 8, 2008
Encysive Pharmaceuticals Inc.
 
(Exact name of registrant as specified in its charter)
         
Delaware   0-20117   13-3532643
 
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)
         
4848 Loop Central Drive, Suite 700, Houston, Texas
  77081
(Address of principal executive offices)
  (Zip Code)
Registrant’s telephone number, including area code: 713-796-8822
Not Applicable
 
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 7.01. Regulation FD Disclosure
Item 9.01. Financial Statements and Exhibits
SIGNATURES
EXHIBIT INDEX
Presentation dated January 7-10, 2008

Table of Contents

Item 7.01. Regulation FD Disclosure.
     In accordance with General Instruction B.2. of Form 8-K, the information presented under this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
     Representatives of Encysive Pharmaceuticals Inc. (the “Company”) intend to make presentations beginning on Tuesday, January 8, 2008, at the 26 th Annual JPMorgan Healthcare Conference (the “Conference”), in San Francisco, California, with a formal presentation to be made on Thursday, January 10, 2008 at 10:30 a.m. Pacific time.
     The Company is furnishing herewith data being presented by certain of its executive officers beginning on January 8, 2008 at the Conference. Beginning at 10:30 a.m. Pacific time on Thursday, January 10, 2008, an audio webcast of their remarks and accompanying graphic presentation will be made available on our website at www.encysive.com.
     The Company does not undertake to update the information as posted on its website; however, it may post additional information included in future press releases and Forms 8-K, as well as posting its periodic Exchange Act reports.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
     99.1 Presentation dated January 7-10, 2008.
[SIGNATURE PAGE FOLLOWS]

 

Table of Contents

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
 
       
 
  ENCYSIVE PHARMACEUTICALS INC.    
 
                             (Registrant)    
 
       
Date: January 8, 2008
       
 
  /s/ Paul S. Manierre    
 
       
 
  Paul S. Manierre    
 
  Vice President, General Counsel    

 

Table of Contents

EXHIBIT INDEX
     
Exhibit No.   Description
 
99.1
  Presentation dated January 7-10, 2008.

 

Encysive Pharmaceuticals (MM) (NASDAQ:ENCY)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025 Encysive Pharmaceuticals (MM) 차트를 더 보려면 여기를 클릭.
Encysive Pharmaceuticals (MM) (NASDAQ:ENCY)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025 Encysive Pharmaceuticals (MM) 차트를 더 보려면 여기를 클릭.